1
|
Tseke P, Tsekes P, Griveas I. Use of therapeutic apheresis methods during pregnancy. Transfus Apher Sci 2024; 63:103848. [PMID: 37993288 DOI: 10.1016/j.transci.2023.103848] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2023]
Abstract
This review will focus on the current application of TA in pregnancy and possible aspects for future studies. It seems that scientific interest and field for further research in pregnancy is lately focused in specific removal of pathogens implicated in the physiologic mechanism of pre-eclampsia/HELLP syndrome as well as recurrent pregnancy failure.
Collapse
Affiliation(s)
| | - Petros Tsekes
- Renal Unit, General Hospital of Athens "Alexandra", Greece
| | | |
Collapse
|
2
|
Dumas S, Descroix S. A continuum model for magnetic particle flows in microfluidics applicable from dilute to packed suspensions. LAB ON A CHIP 2024; 24:584-593. [PMID: 38175160 DOI: 10.1039/d3lc00416c] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/05/2024]
Abstract
The manipulation of magnetic microparticles has always been pivotal in the development of microfluidic devices, as it encompasses a broad range of applications, such as drug delivery, bioanalysis, on-chip diagnostics, and more recently organ-on-chip development. However, predicting the behavior and trajectory of these particles remains a recurring and partly unresolved question. Magnetic particle-laden flows can display intricate collective behaviors, such as packed plugs, column-shaped aggregates, or fluidization, which are difficult to predict. In this study, we introduce a finite-element model to simulate highly dense flows of magnetic microparticles. Our method relies on an interpenetrating continuum approach, where both the liquid and particle phases are described by the Navier-Stokes equations, in which the magnetic force, interphase friction, and interparticle forces were included. We demonstrate its applicability across the entire range of particle packing densities and compare the results with experimental data from real microfluidic application cases. The model successfully replicates complex behaviors, such as particle aggregation, plug formation and fluidization. This approach has potential to accelerate microfluidic device development by reducing the need for costly and time-consuming experimental optimization.
Collapse
Affiliation(s)
- Simon Dumas
- Institut Curie, Laboratoire PhysicoChimie (CNRS UMR 168), Institut Pierre-Gilles de Gennes, Sorbonne Université, PSL Research University, 6 rue Jean Calvin, 75005 Paris, France.
| | - Stéphanie Descroix
- Institut Curie, Laboratoire PhysicoChimie (CNRS UMR 168), Institut Pierre-Gilles de Gennes, Sorbonne Université, PSL Research University, 6 rue Jean Calvin, 75005 Paris, France.
| |
Collapse
|
3
|
Alexandre L, Araya-Farias M, Nguyen ML, Naoumi N, Gropplero G, Gizeli E, Malaquin L, Descroix S. High-throughput extraction on a dynamic solid phase for low-abundance biomarker isolation from biological samples. MICROSYSTEMS & NANOENGINEERING 2023; 9:109. [PMID: 37680311 PMCID: PMC10480215 DOI: 10.1038/s41378-023-00582-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/13/2023] [Revised: 06/25/2023] [Accepted: 07/13/2023] [Indexed: 09/09/2023]
Abstract
Liquid biopsy, in particular circulating tumor DNA (ctDNA) analysis, has paved the way for a new noninvasive approach to cancer diagnosis, treatment selection and follow-up. As a crucial step in the analysis, the extraction of the genetic material from a complex matrix needs to meet specific requirements such as high specificity and low loss of target. Here, we developed a new generation of microfluidic fluidized beds (FBs) that enable the efficient extraction and preconcentration of specific ctDNA sequences from human serum with flow rates up to 15 µL/min. We first demonstrated that implementation of a vibration system inducing flow rate fluctuations combined with a mixture of different bead sizes significantly enhanced bead homogeneity, thereby increasing capture efficiency. Taking advantage of this new generation of high-throughput magnetic FBs, we then developed a new method to selectively capture a double-stranded (dsDNA) BRAF mutated DNA sequence in complex matrices such as patient serum. Finally, as proof of concept, ligation chain reaction (LCR) assays were performed to specifically amplify a mutated BRAF sequence, allowing the detection of concentrations as low as 6 × 104 copies/µL of the mutated DNA sequence in serum.
Collapse
Affiliation(s)
- Lucile Alexandre
- Laboratoire Physico-Chimie Curie, CNRS UMR 168, Institut Curie, PSL Research University, Paris, France
- Institut Pierre-Gilles de Gennes (IPGG), Sorbonne University, Paris, France
| | - Monica Araya-Farias
- Laboratoire Physico-Chimie Curie, CNRS UMR 168, Institut Curie, PSL Research University, Paris, France
- Institut Pierre-Gilles de Gennes (IPGG), Sorbonne University, Paris, France
- Present Address: Frédéric Joliot Institute for Life Sciences, Pharmacology and Immunoanalysis Unit, Immunoanalysis Studies and Research Laboratory, Alternative Energies and Atomic Energy Commission (CEA), Gif-sur-Yvette, France
| | - Manh-Louis Nguyen
- Laboratoire Physico-Chimie Curie, CNRS UMR 168, Institut Curie, PSL Research University, Paris, France
- Institut Pierre-Gilles de Gennes (IPGG), Sorbonne University, Paris, France
| | - Nikoletta Naoumi
- Department of Biology, University of Crete, Heraklion, Greece
- Institute of Molecular Biology and Biotechnology (IMBB) - FORTH, Heraklion, Greece
| | - Giacomo Gropplero
- Laboratoire Physico-Chimie Curie, CNRS UMR 168, Institut Curie, PSL Research University, Paris, France
- Institut Pierre-Gilles de Gennes (IPGG), Sorbonne University, Paris, France
| | - Electra Gizeli
- Department of Biology, University of Crete, Heraklion, Greece
- Institute of Molecular Biology and Biotechnology (IMBB) - FORTH, Heraklion, Greece
| | - Laurent Malaquin
- Laboratoire d’analyse et d’architecture des systèmes (LAAS) CNRS, Elia Group, Toulouse, France
| | - Stéphanie Descroix
- Laboratoire Physico-Chimie Curie, CNRS UMR 168, Institut Curie, PSL Research University, Paris, France
- Institut Pierre-Gilles de Gennes (IPGG), Sorbonne University, Paris, France
| |
Collapse
|
4
|
Chaemsaithong P, Gil MM, Chaiyasit N, Cuenca-Gomez D, Plasencia W, Rolle V, Poon LC. Accuracy of placental growth factor alone or in combination with soluble fms-like tyrosine kinase-1 or maternal factors in detecting preeclampsia in asymptomatic women in the second and third trimesters: a systematic review and meta-analysis. Am J Obstet Gynecol 2023; 229:222-247. [PMID: 36990308 DOI: 10.1016/j.ajog.2023.03.032] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2022] [Revised: 03/09/2023] [Accepted: 03/15/2023] [Indexed: 03/30/2023]
Abstract
OBJECTIVE This study aimed to: (1) identify all relevant studies reporting on the diagnostic accuracy of maternal circulating placental growth factor) alone or as a ratio with soluble fms-like tyrosine kinase-1), and of placental growth factor-based models (placental growth factor combined with maternal factors±other biomarkers) in the second or third trimester to predict subsequent development of preeclampsia in asymptomatic women; (2) estimate a hierarchical summary receiver-operating characteristic curve for studies reporting on the same test but different thresholds, gestational ages, and populations; and (3) select the best method to screen for preeclampsia in asymptomatic women during the second and third trimester of pregnancy by comparing the diagnostic accuracy of each method. DATA SOURCES A systematic search was performed through MEDLINE, Embase, CENTRAL, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform databases from January 1, 1985 to April 15, 2021. STUDY ELIGIBILITY CRITERIA Studies including asymptomatic singleton pregnant women at >18 weeks' gestation with risk of developing preeclampsia were evaluated. We included only cohort or cross-sectional test accuracy studies reporting on preeclampsia outcome, allowing tabulation of 2×2 tables, with follow-up available for >85%, and evaluating performance of placental growth factor alone, soluble fms-like tyrosine kinase-1- placental growth factor ratio, or placental growth factor-based models. The study protocol was registered on the International Prospective Register Of Systematic Reviews (CRD 42020162460). METHODS Because of considerable intra- and interstudy heterogeneity, we computed the hierarchical summary receiver-operating characteristic plots and derived diagnostic odds ratios, β, θi, and Λ for each method to compare performances. The quality of the included studies was evaluated by the QUADAS-2 tool. RESULTS The search identified 2028 citations, from which we selected 474 studies for detailed assessment of the full texts. Finally, 100 published studies met the eligibility criteria for qualitative and 32 for quantitative syntheses. Twenty-three studies reported on performance of placental growth factor testing for the prediction of preeclampsia in the second trimester, including 16 (with 27 entries) that reported on placental growth factor test alone, 9 (with 19 entries) that reported on the soluble fms-like tyrosine kinase-1-placental growth factor ratio, and 6 (16 entries) that reported on placental growth factor-based models. Fourteen studies reported on performance of placental growth factor testing for the prediction of preeclampsia in the third trimester, including 10 (with 18 entries) that reported on placental growth factor test alone, 8 (with 12 entries) that reported on soluble fms-like tyrosine kinase-1-placental growth factor ratio, and 7 (with 12 entries) that reported on placental growth factor-based models. For the second trimester, Placental growth factor-based models achieved the highest diagnostic odds ratio for the prediction of early preeclampsia in the total population compared with placental growth factor alone and soluble fms-like tyrosine kinase-1-placental growth factor ratio (placental growth factor-based models, 63.20; 95% confidence interval, 37.62-106.16 vs soluble fms-like tyrosine kinase-1-placental growth factor ratio, 6.96; 95% confidence interval, 1.76-27.61 vs placental growth factor alone, 5.62; 95% confidence interval, 3.04-10.38); placental growth factor-based models had higher diagnostic odds ratio than placental growth factor alone for the identification of any-onset preeclampsia in the unselected population (28.45; 95% confidence interval, 13.52-59.85 vs 7.09; 95% confidence interval, 3.74-13.41). For the third trimester, Placental growth factor-based models achieved prediction for any-onset preeclampsia that was significantly better than that of placental growth factor alone but similar to that of soluble fms-like tyrosine kinase-1-placental growth factor ratio (placental growth factor-based models, 27.12; 95% confidence interval, 21.67-33.94 vs placental growth factor alone, 10.31; 95% confidence interval, 7.41-14.35 vs soluble fms-like tyrosine kinase-1-placental growth factor ratio, 14.94; 95% confidence interval, 9.42-23.70). CONCLUSION Placental growth factor with maternal factors ± other biomarkers determined in the second trimester achieved the best predictive performance for early preeclampsia in the total population. However, in the third trimester, placental growth factor-based models had predictive performance for any-onset preeclampsia that was better than that of placental growth factor alone but similar to that of soluble fms-like tyrosine kinase-1-placental growth factor ratio. Through this meta-analysis, we have identified a large number of very heterogeneous studies. Therefore, there is an urgent need to develop standardized research using the same models that combine serum placental growth factor with maternal factors ± other biomarkers to accurately predict preeclampsia. Identification of patients at risk might be beneficial for intensive monitoring and timing delivery.
Collapse
Affiliation(s)
- Piya Chaemsaithong
- Department of Obstetrics and Gynecology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | - María M Gil
- Department of Obstetrics and Gynecology, Hospital Universitario de Torrejón, Torrejón de Ardoz, Madrid, Spain; Faculty of Health Sciences, Universidad Francisco de Vitoria, Madrid, Spain
| | - Noppadol Chaiyasit
- Maternal Fetal Medicine Division, Department of Obstetrics and Gynecology, King Chulalongkorn Memorial Hospital, Bangkok, Thailand
| | - Diana Cuenca-Gomez
- Department of Obstetrics and Gynecology, Hospital Universitario de Torrejón, Torrejón de Ardoz, Madrid, Spain
| | - Walter Plasencia
- Department of Obstetrics and Gynecology, Complejo Hospitalario Universitario de Canarias, San Cristóbal de La Laguna, Spain
| | - Valeria Rolle
- Biostatistics and Epidemiology Unit, Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain
| | - Liona C Poon
- Department of Obstetrics and Gynaecology, Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region.
| |
Collapse
|
5
|
Rduch T, Arn N, Kinkel J, Fischer T, Binet I, Hornung R, Herrmann IK. Magnetic blood purification-based soluble fms-like tyrosine kinase-1 removal in comparison with dextran sulfate apheresis and therapeutic plasma exchange. Artif Organs 2023; 47:1309-1318. [PMID: 36995348 DOI: 10.1111/aor.14531] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2022] [Revised: 03/17/2023] [Accepted: 03/23/2023] [Indexed: 03/31/2023]
Abstract
BACKGROUND Preeclampsia remains one of the most serious complications of pregnancy. Effective therapies are yet to be developed. Recent research has identified an imbalance of angiogenic and antiangiogenic factors as a root cause of preeclampsia. In particular, soluble fms-like tyrosine kinase-1 (sFlt-1) has been shown to bind the angiogenic factors vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), reducing blood vessel growth. Increasing preclinical and clinical evidence suggests that removal of the sFlt-1 protein may benefit patients with early onset preeclampsia. sFlt-1 may be removed by conventional blood purification techniques, such as therapeutic plasma exchange (TPE) and dextran sulfate apheresis (DSA), or emerging technologies, including extracorporeal magnetic blood purification (MBP). METHODS We compare the performance and selectivity of TPE, DSA, and MBP for the therapeutic removal of sFlt-1. For MPB, we employ magnetic nanoparticles functionalized with either sFlt-1 antibodies or the sFlt-1-binding partner, vascular endothelial growth factor (VEGF). RESULTS We demonstrate that sFlt-1 removal by MBP is feasible and significantly more selective than TPE and DSA at comparable sFlt-1 removal efficiencies (MBP 96%, TPE 92%, DSA 78%). During both TPE and DSA, complement factors (incl. C3c and C4) are depleted to a considerable extent (-90% for TPE, -55% for DSA), while in MBP, complement factor concentrations remain unaltered. We further demonstrate that the removal efficacy of sFlt-1 in the MBP approach is strongly dependent on the nanoparticle type and dose and can be optimized to reach clinically feasible throughputs. CONCLUSIONS Taken together, the highly selective removal of sFlt-1 and potential other disease-causing factors by extracorporeal magnetic blood purification may offer new prospects for preeclamptic patients.
Collapse
Affiliation(s)
- Thomas Rduch
- Department of Gynaecology, Cantonal Hospital St. Gallen, Rorschacherstrasse 95, St. Gallen, Switzerland
- Laboratory for Particles-Biology Interactions, Department of Materials Meet Life, Swiss Federal Laboratories for Materials Science and Technology (Empa), Lerchenfeldstrasse 5, St. Gallen, Switzerland
| | - Norbert Arn
- Clinic for Nephrology and Transplant Medicine, Cantonal Hospital St.Gallen, Rorschacherstrasse 95, St.Gallen, Switzerland
| | - Janis Kinkel
- Department of Gynaecology, Cantonal Hospital St. Gallen, Rorschacherstrasse 95, St. Gallen, Switzerland
| | - Tina Fischer
- Department of Gynaecology, Cantonal Hospital St. Gallen, Rorschacherstrasse 95, St. Gallen, Switzerland
| | - Isabelle Binet
- Clinic for Nephrology and Transplant Medicine, Cantonal Hospital St.Gallen, Rorschacherstrasse 95, St.Gallen, Switzerland
| | - René Hornung
- Department of Gynaecology, Cantonal Hospital St. Gallen, Rorschacherstrasse 95, St. Gallen, Switzerland
| | - Inge K Herrmann
- Laboratory for Particles-Biology Interactions, Department of Materials Meet Life, Swiss Federal Laboratories for Materials Science and Technology (Empa), Lerchenfeldstrasse 5, St. Gallen, Switzerland
- Department of Mechanical and Process Engineering, ETH Zurich, Nanoparticle Systems Engineering Laboratory, Institute of Energy and Process Engineering, Sonneggstrasse 3, Zurich, Switzerland
| |
Collapse
|
6
|
Ren Y, YaneYang, Lu Q, Wang Q, Lu G, Wei Y, Zhou J. Transcription factor cellular promoter 2 is required for upstream binding protein 1 -mediated angiogenesis. Gene Expr Patterns 2023; 48:119308. [PMID: 36889372 DOI: 10.1016/j.gep.2023.119308] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2022] [Revised: 11/22/2022] [Accepted: 03/04/2023] [Indexed: 03/08/2023]
Abstract
OBJECTIVE Angiogenesis is a key process of repairing tissue damage, and it is regulated by the delicate balance between anti-angiogenesis factors. In the present study, we investigate whether transcription factor cellular promoter 2 (TFCP2) is required for upstream binding protein 1 (UBP1)-mediated angiogenesis. METHODS Levels of UBP1 and TFCP2 in human umbilical vein endothelial cells (HUVECs) are detected by quantitative polymerase chain reaction (q-PCR) and Western blotting (WB). Effects of UBP1 on angiogenesis and migration are detected by tube-like network formation on matrigel assay and scratch assay. The interaction between UBP1 and TFCP2 is predicted and verified by STRING and Co-immunoprecipitation (Co-IP). RESULTS Firstly, the UBP1 expression level was up-regulated in the stimuli of vascular endothelial growth factor (VEGF) in HUVECs, and the knockdown of UBP1 inhibited angiogenesis and migration of HUVECs. Then, UBP1 interacted with TFCP2. Besides, the TFCP2 expression level was up-regulated in VEGF-stimulated HUVECs. Furthermore, knockdown of TFCP2 inhibited angiogenesis and migration in VEGF-stimulated HUVECs, and down-regulation of UBP1 enhanced the inhibition. CONCLUSION TFCP2 also plays a key role in UBP1 mediated angiogenesis of HUVECs stimulated by VEGF. These findings will provide a new theoretical basis for the treatment of angiogenic diseases.
Collapse
Affiliation(s)
- Yanyan Ren
- Department of Neurology, Liaocheng Third People's Hospital, No. 62 Weiyu Road, Dongchangfu District, Liaocheng, Shandong, 252000, China
| | - YaneYang
- The Second Department of Neurology, Gaotang People's Hospital, North of Provincial Road No.520 and West of Binhu Road, Gaotang County, Liaocheng, Shandong, 252800, China
| | - Qingbo Lu
- Department of Emergency, Ningyang First People's Hospital, No. 872, Jinyang Street, Ningyang County, Tai'an, Shandong, 271400, China
| | - Qiang Wang
- Department of Neurosurgery, Gaoqing People's Hospital, Gaoqing People's Hospital of Zibo City, Shandong, 256300, China
| | - Gentao Lu
- The Third Department of Neurology, Ningyang First People's Hospital, No.872 Jinyang Road, Ningyang County, Tai'an, Shandong, 271400, China
| | - Yanli Wei
- Department of Respiratory and Critical Care, First Hospital of Zibo City, No.4 Emeishan East Road, Boshan District, Zibo City, Shandong, 255200, China
| | - Jiaqi Zhou
- Department of Traditional Chinese Medicine, Wujin Hospital Affiliated with Jiangsu University, Changzhou, Jiangsu, 213017, China; Department of Traditional Chinese Medicine, The Wujin Clinical College of Xuzhou Medical University, Changzhou, Jiangsu, 213017, China.
| |
Collapse
|
7
|
Vatish M, Powys VR, Cerdeira AS. Novel therapeutic and diagnostic approaches for preeclampsia. Curr Opin Nephrol Hypertens 2023; 32:124-133. [PMID: 36683536 DOI: 10.1097/mnh.0000000000000870] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
PURPOSE OF REVIEW This review will summarize recent findings relating to the diagnostic approach to preeclampsia and current avenues of research aimed at modifying the underlying disease process. RECENT FINDINGS Growing international consensus supports a broad preeclampsia definition that incorporates maternal end-organ and uteroplacental dysfunction. Recent evidence demonstrates that this definition better identifies women and babies at risk of adverse outcomes compared to the traditional definition of hypertension and proteinuria. Multiple studies have demonstrated the usefulness and cost-effectiveness of angiogenic biomarkers such as soluble fms-like tyrosine kinase-1 and placental growth factor as a clinical adjunct to diagnose and predict severity of preeclampsia associated outcomes. Current novel therapeutic approaches to preeclampsia target pathogenic pathways (e.g. antiangiogenesis) or downstream effects such as oxidative stress and nitric oxide. Recent findings relating to these promising candidates are discussed. Multicenter clinical trials are needed to evaluate their effectiveness and ability to improve fetal and maternal outcomes. SUMMARY We provide an updated framework of the current approaches to define and diagnose preeclampsia. Disease modifying therapies (in particular, targeting the angiogenic pathway) are being developed for the first time and promise to revolutionize the way we manage preeclampsia.
Collapse
Affiliation(s)
- Manu Vatish
- Nuffield Department of Women's Health and Reproductive Research, University of Oxford, Oxford
| | | | - Ana Sofia Cerdeira
- Nuffield Department of Women's Health and Reproductive Research, University of Oxford, Oxford
| |
Collapse
|
8
|
Alexandre L, Bendali A, Pereiro I, Azimani M, Dumas S, Malaquin L, Mai TD, Descroix S. Modular microfluidic system for on-chip extraction, preconcentration and detection of the cytokine biomarker IL-6 in biofluid. Sci Rep 2022; 12:9468. [PMID: 35676309 PMCID: PMC9176165 DOI: 10.1038/s41598-022-13304-z] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2022] [Accepted: 05/04/2022] [Indexed: 12/17/2022] Open
Abstract
The cytokine interleukin 6 (IL-6) is involved in the pathogenesis of different inflammatory diseases, including cancer, and its monitoring could help diagnosis, prognosis of relapse-free survival and recurrence. Here, we report an innovative microfluidic approach that uses the fluidization of magnetic beads to specifically extract, preconcentrate and fluorescently detect IL-6 directly on-chip. We assess how the physical properties of the beads can be tuned to improve assay performance by enhancing mass transport, reduce non-specific binding and multiply the detection signal threefold by transitioning between packed and fluidization states. With the integration of a full ELISA protocol in a single microfluidic chamber, we show a twofold reduction in LOD compared to conventional methods along with a large dynamic range (10 pg/mL to 2 ng/mL). We additionally demonstrate its application to IL-6 detection in undiluted serum samples.
Collapse
|
9
|
LI MINGQUN, GUO HONGYAN, XI HONGLI, ZHOU SUFEN. A STUDY ON THE CORRELATION BETWEEN THE ENDOTHELIN-1, NITRIC OXIDE FUNCTION AND THE RENAL HEMODYNAMICS IN PATIENTS WITH HYPERTENSIVE DISORDERS IN PREGNANCY IN HUBEI. J MECH MED BIOL 2021. [DOI: 10.1142/s0219519421400467] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Objective: To analyze the correlation between the vascular endothelial function (characterized by endothelin-1 and nitric oxide) and the renal hemodynamics in patients with hypertensive disorders in pregnancy (HDP) by color Doppler ultrasound. Method: Depending on the severity of the disease, 76 HDP patients were divided into three groups, namely, pregnancy-induced hypertension (PIH) group ([Formula: see text]), mild preeclampsia (PE) group ([Formula: see text]), and severe PE group ([Formula: see text]). In the meantime, 28 healthy pregnant women were selected as controls. Color Doppler ultrasound was performed to determine the following parameters in the interlobar arteries of the kidney: Resistance index (RI), peak end-diastolic velocity (EDV), pulsatility index (PI), peak systolic velocity (PSV), and S/D ratio. The correlations of these parameters with the serum levels of ET-1 and NO were then analyzed. Result: (1) In the interlobar arteries of the kidney, RI, S/D, PI were positively significantly correlated to the serum level of ET-1 in HDP patients (All [Formula: see text]) and negatively to the serum level of NO (All [Formula: see text]). (2) RI, S/D, PI of the mild and severe PE groups were significantly higher than those of the control group (All [Formula: see text]). However, EDV of the mild and severe PE groups was significantly lower than that of the control group (All [Formula: see text]). (3) The serum level of ET-1 was significantly higher in the HDP patients than in the control group ([Formula: see text]). However, the serum level of NO was significantly lower in the former than in the latter ([Formula: see text]). As HDP became more severe, there was an elevation in the serum level of ET-1 and a decrease in NO. Conclusion: Indicators of renal hemodynamics measured by color Doppler ultrasound were correlated to the serum levels of ET-1 and NO characterizing the vascular endothelial function. They were sensitive indicators reflecting hemodynamic changes and renal impairment in HDP patients.
Collapse
Affiliation(s)
- MINGQUN LI
- Department of Obstetrics and Gynecology, Xiangyang No. 1 People’s Hospital, Hubei University of Medicine, Xiangyang 441000, P. R. China
| | - HONG YAN GUO
- Department of Obstetrics and Gynecology, Xiangyang No. 1 People’s Hospital, Hubei University of Medicine, Xiangyang 441000, P. R. China
| | - HONG LI XI
- Department of Obstetrics and Gynecology, Xiangyang No. 1 People’s Hospital, Hubei University of Medicine, Xiangyang 441000, P. R. China
| | - SU FEN ZHOU
- Department of Ultrasound, Xiangyang No. 1 People’s Hospital, Hubei University of Medicine Xiangyang 441000, P. R. China
| |
Collapse
|
10
|
Bodke VV, Burdette JE. Advancements in Microfluidic Systems for the Study of Female Reproductive Biology. Endocrinology 2021; 162:6225875. [PMID: 33852726 PMCID: PMC8571709 DOI: 10.1210/endocr/bqab078] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/31/2020] [Indexed: 12/11/2022]
Abstract
The female reproductive tract is a highly complex physiological system that consists of the ovaries, fallopian tubes, uterus, cervix, and vagina. An enhanced understanding of the molecular, cellular, and genetic mechanisms of the tract will allow for the development of more effective assisted reproductive technologies, therapeutics, and screening strategies for female specific disorders. Traditional 2-dimensional and 3-dimensional static culture systems may not always reflect the cellular and physical contexts or physicochemical microenvironment necessary to understand the dynamic exchange that is crucial for the functioning of the reproductive system. Microfluidic systems present a unique opportunity to study the female reproductive tract, as these systems recapitulate the multicellular architecture, contacts between different tissues, and microenvironmental cues that largely influence cell structure, function, behavior, and growth. This review discusses examples, challenges, and benefits of using microfluidic systems to model ovaries, fallopian tubes, endometrium, and placenta. Additionally, this review also briefly discusses the use of these systems in studying the effects of endocrine disrupting chemicals and diseases such as ovarian cancer, preeclampsia, and polycystic ovarian syndrome.
Collapse
Affiliation(s)
- Vedant V Bodke
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago 60607, USA
| | - Joanna E Burdette
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago 60607, USA
- Correspondence: Joanna E. Burdette, PhD, University of Illinois at Chicago, 900 S. Ashland Ave, Chicago, IL 60607, USA.
| |
Collapse
|
11
|
Hong K, Park HJ, H Cha D. Clinical implications of placenta-derived angiogenic/anti-angiogenic biomarkers in pre-eclampsia. Biomark Med 2021; 15:523-536. [PMID: 33856265 DOI: 10.2217/bmm-2020-0545] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Pre-eclampsia (PE) is a devastating systemic disease which results in maternal hypertension with multi-organ failure due to angiogenic imbalance, characterized by lack of circulating pro-angiogenic factors and excess of anti-angiogenic factors. These factors are crucial for understanding the pathophysiology of PE since they serve as a critical link from placental dysfunction to the clinical syndrome of systemic endothelial dysfunction in the disease. Moreover, utilizing these angiogenic/anti-angiogenic biomarkers can be helpful in risk stratifying and the early detection of PE, which allows for timely intervention to improve maternal and neonatal outcomes. In this review, we summarize updated perspectives of the angiogenic imbalance in PE with detailed characterization of key factors involved in the pathogenesis and how the developed biomarkers can be used in clinical settings as diagnostic tools and as possible therapeutic targets of PE.
Collapse
Affiliation(s)
- Kirim Hong
- Department of Obstetrics & Gynecology, Gangnam CHA Medical Center, CHA University, Seoul, Korea
| | - Hee J Park
- Department of Obstetrics & Gynecology, Gangnam CHA Medical Center, CHA University, Seoul, Korea
| | - Dong H Cha
- Department of Obstetrics & Gynecology, Gangnam CHA Medical Center, CHA University, Seoul, Korea
| |
Collapse
|
12
|
Wang X, Yang L, Chen Y, Zhang L, Fei H. Ghrelin promotes angiogenesis by activating the Jagged1/Notch2/VEGF pathway in preeclampsia. J Obstet Gynaecol Res 2020; 47:486-494. [PMID: 33145927 DOI: 10.1111/jog.14555] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2020] [Revised: 10/02/2020] [Accepted: 10/16/2020] [Indexed: 12/24/2022]
Abstract
AIM Ghrelin, an endogenous ligand for the growth hormone secretagogue receptor (GHSR), has been found to be involved in the regulation of blood pressure; however, its effects in preeclampsia (PE) and the potential underlying mechanism remain poorly understood. In this study, we aimed to investigate the correlation between ghrelin and PE and reveal the possible mechanism underlying any relationship. METHODS The levels of ghrelin and VEGF in the plasma of 6 early-onset PE (EOPE), 6 late-onset PE (LOPE) and 12 healthy pregnant (HP) women were detected using enzyme-linked immunosorbent assay (ELISA). The recombinant plasmid, pCDH-ghrelin, was designed to overexpress ghrelin in human umbilical vein endothelial cells (HUVECs). We analyzed angiogenesis in vitro and investigated the mechanism using MTT assay, colony formation assay, transwell migration assay, Matrigel-induced tube formation assay and western blotting. RESULTS Ghrelin was significantly decreased in EOPE patients (P < 0.05) but elevated in LOPE patients compared to HP groups (P > 0.05). There was a significant decrease in plasma level of VEGF in EOPE and LOPE patients compared to the controls (P < 0.05). The proliferation, migration and tube formation ability of HUVECs were enhanced after transfection with pCDH-ghrelin. Ghrelin increased VEGF by activating the Jagged1/Notch2 pathway. CONCLUSION Our study uncovered that ghrelin has the potential to improve endothelial function by promoting angiogenesis through Jagged1/Notch2/VEGF pathway.
Collapse
Affiliation(s)
- Xiaoqin Wang
- Department of Gynecology and Obstetrics, Shanghai Fifth People's Hospital, Fudan University, Shanghai, China
| | - Lina Yang
- Department of Gynecology and Obstetrics, Shanghai Fifth People's Hospital, Fudan University, Shanghai, China
| | - Yaping Chen
- Department of Gynecology and Obstetrics, Shanghai Fifth People's Hospital, Fudan University, Shanghai, China
| | - Liwen Zhang
- Department of Gynecology and Obstetrics, Shanghai Fifth People's Hospital, Fudan University, Shanghai, China
| | - He Fei
- Department of Gynecology and Obstetrics, Shanghai Fifth People's Hospital, Fudan University, Shanghai, China
| |
Collapse
|
13
|
Zhong M, Peng J, Xiang L, Yang X, Wang X, Zhu Y. Epigallocatechin Gallate (EGCG) Improves Anti-Angiogenic State, Cell Viability, and Hypoxia-Induced Endothelial Dysfunction by Downregulating High Mobility Group Box 1 (HMGB1) in Preeclampsia. Med Sci Monit 2020; 26:e926924. [PMID: 33056943 PMCID: PMC7574359 DOI: 10.12659/msm.926924] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Background Preeclampsia (PE) is a serious complication of pregnancy with no effective therapy. This study assessed whether epigallocatechin gallate (EGCG) could reduce the production of anti-angiogenic factors, improve cell viability, and suppress endothelial dysfunction in vitro via regulating high mobility group box 1 (HMGB1) in preeclampsia. Material/Methods Human umbilical vein endothelial cells (HUVECs) grown in conditioned medium from hypoxic JEG-3 cells were used to investigate the effects of EGCG on anti-angiogenic state, cell viability, and markers of endothelial dysfunction. To confirm that EGCG exerted its effects via HMGB1, we also examined the impact of EGCG on anti-angiogenic state, cell viability, and endothelial dysfunction following HMGB1 treatment in vitro. Results EGCG inhibited HMGB1 expression in hypoxic trophoblast cells in a dose-dependent manner. In addition, EGCG relieved anti-angiogenic state and endothelial dysfunction in hypoxic trophoblast cells by downregulating HMGB1. Moreover, EGCG dose-dependently promoted cell proliferation by downregulating HMGB1. Conclusions Taken together, our data show the protective role of EGCG in preeclampsia and revealed EGCG-mediated effects on the production of anti-angiogenic factors, cell viability, and endothelial dysfunction through downregulating HMGB1. These observations suggest that EGCG is a novel therapeutic candidate for preeclampsia.
Collapse
Affiliation(s)
- Min Zhong
- Department of Obstetrics, People's Hospital of Longhua Shenzhen, Shenzhen, Guangdong, China (mainland)
| | - Julan Peng
- Department of Obstetrics, People's Hospital of Longhua Shenzhen, Shenzhen, Guangdong, China (mainland)
| | - Lanhua Xiang
- Department of Obstetrics, People's Hospital of Longhua Shenzhen, Shenzhen, Guangdong, China (mainland)
| | - Xinhuang Yang
- Department of Obstetrics, People's Hospital of Longhua Shenzhen, Shenzhen, Guangdong, China (mainland)
| | - Xianghua Wang
- Department of Obstetrics, People's Hospital of Longhua Shenzhen, Shenzhen, Guangdong, China (mainland)
| | - Yanbin Zhu
- Department of Obstetrics, Shenzhen Hospital of Southern Medical University, Shenzhen, Guangdong, China (mainland)
| |
Collapse
|
14
|
Cerdeira AS, Vatish M, Lecarpentier E. One Step Closer to a Cure for Preeclampsia?: Boosting the Natural Affinity of VEGF (Vascular Endothelial Growth Factor) to sFlt (Soluble fms-Like Tyrosine Kinase)-1. Hypertension 2020; 76:1081-1083. [PMID: 32903106 DOI: 10.1161/hypertensionaha.120.15112] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Ana Sofia Cerdeira
- From the Nuffield Department of Women's & Reproductive Health University of Oxford, United Kingdom (A.S.C., M.V.)
| | - Manu Vatish
- From the Nuffield Department of Women's & Reproductive Health University of Oxford, United Kingdom (A.S.C., M.V.)
| | - Edouard Lecarpentier
- Department of Obstetrics and Gynecology, Centre Hospitalier Intercommunal de Creteil, University Paris Est Créteil, France (E.L.)
| |
Collapse
|
15
|
Matin M, Mörgelin M, Stetefeld J, Schermer B, Brinkkoetter PT, Benzing T, Koch M, Hagmann H. Affinity-Enhanced Multimeric VEGF (Vascular Endothelial Growth Factor) and PlGF (Placental Growth Factor) Variants for Specific Adsorption of sFlt-1 to Restore Angiogenic Balance in Preeclampsia. Hypertension 2020; 76:1176-1184. [PMID: 32623922 DOI: 10.1161/hypertensionaha.120.14974] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Preeclampsia is a potentially life-threatening multisystem disease affecting 4% to 8% of pregnant women after the 20th week of gestation. An excess of placental expressed antiangiogenic soluble VEGF (vascular endothelial growth factor)-receptor 1 (soluble FMS-like tyrosine kinase 1) scavenges VEGF and PlGF (placental growth factor), causing generalized endothelial dysfunction. Interventions to restore the angiogenic balance in preeclamptic pregnancies are intensively studied and improve maternal and neonatal outcomes. Especially extracorporeal strategies to remove sFlt-1 are promising in human pregnancy. However, available apheresis systems adsorb sFlt-1 unspecifically and with low efficiency. Affinity-enhanced ligands are needed to improve performance and compatibility of apheresis treatments. Using computerized molecular modeling, we developed multimeric VEGF molecules comprised of single-chain VEGF165 dimers (scVEGF165). A short peptide linker hampers intrachain dimerization to induce assembly preferably as tetrameric molecules as visualized in negative staining electron microscopy. scVEGF165 multimers possess 1.2-fold higher affinity for sFlt-1 as compared to the available antibodies or monomeric VEGF. Consequently, scVEGF multimers have the ability to competitively release sFlt-1 bound PlGF and, in particular, VEGF. In ex vivo adsorption experiments using serum samples from patients with preeclampsia, scVEGF multimers reduce sFlt-1 levels by 85% and increase PlGF and VEGF levels by 20- and 9-fold, respectively. Finally, performance and stability of sFlt-1 capturing scVEGF165 multimers were scrutinized on different matrices of which biocompatible agarose matrix yielded optimal results. We introduce the first VEGF-based highly efficient sFlt-1 apheresis system that is directly applicable in vivo due to utilization of inert agarose matrix, using a homomultimeric form of VEGF165 to restore the angiogenic balance in preeclampsia.
Collapse
Affiliation(s)
- Mahsa Matin
- From the Department II of Internal Medicine (M. Matin, B.S., P.T.B., T.B., H.H.), University of Cologne, Faculty of Medicine, University Hospital Cologne, Germany.,Center for Molecular Medicine Cologne (M. Matin, B.S., P.T.B., T.B., M.K., H.H.), University of Cologne, Faculty of Medicine, University Hospital Cologne, Germany.,CECAD (M. Matin, B.S., P.T.B., T.B., H.H.), University of Cologne, Faculty of Medicine, University Hospital Cologne, Germany
| | | | | | - Bernhard Schermer
- From the Department II of Internal Medicine (M. Matin, B.S., P.T.B., T.B., H.H.), University of Cologne, Faculty of Medicine, University Hospital Cologne, Germany.,Center for Molecular Medicine Cologne (M. Matin, B.S., P.T.B., T.B., M.K., H.H.), University of Cologne, Faculty of Medicine, University Hospital Cologne, Germany.,CECAD (M. Matin, B.S., P.T.B., T.B., H.H.), University of Cologne, Faculty of Medicine, University Hospital Cologne, Germany
| | - Paul T Brinkkoetter
- From the Department II of Internal Medicine (M. Matin, B.S., P.T.B., T.B., H.H.), University of Cologne, Faculty of Medicine, University Hospital Cologne, Germany.,Center for Molecular Medicine Cologne (M. Matin, B.S., P.T.B., T.B., M.K., H.H.), University of Cologne, Faculty of Medicine, University Hospital Cologne, Germany.,CECAD (M. Matin, B.S., P.T.B., T.B., H.H.), University of Cologne, Faculty of Medicine, University Hospital Cologne, Germany
| | - Thomas Benzing
- From the Department II of Internal Medicine (M. Matin, B.S., P.T.B., T.B., H.H.), University of Cologne, Faculty of Medicine, University Hospital Cologne, Germany.,Center for Molecular Medicine Cologne (M. Matin, B.S., P.T.B., T.B., M.K., H.H.), University of Cologne, Faculty of Medicine, University Hospital Cologne, Germany.,CECAD (M. Matin, B.S., P.T.B., T.B., H.H.), University of Cologne, Faculty of Medicine, University Hospital Cologne, Germany
| | - Manuel Koch
- Center for Molecular Medicine Cologne (M. Matin, B.S., P.T.B., T.B., M.K., H.H.), University of Cologne, Faculty of Medicine, University Hospital Cologne, Germany.,Institute for Dental Research and Oral Musculoskeletal Biology, Center for Biochemistry, University of Cologne, Germany (M.K.)
| | - Henning Hagmann
- From the Department II of Internal Medicine (M. Matin, B.S., P.T.B., T.B., H.H.), University of Cologne, Faculty of Medicine, University Hospital Cologne, Germany.,Center for Molecular Medicine Cologne (M. Matin, B.S., P.T.B., T.B., M.K., H.H.), University of Cologne, Faculty of Medicine, University Hospital Cologne, Germany.,CECAD (M. Matin, B.S., P.T.B., T.B., H.H.), University of Cologne, Faculty of Medicine, University Hospital Cologne, Germany
| |
Collapse
|
16
|
Targeting angiogenesis and lymphangiogenesis in kidney disease. Nat Rev Nephrol 2020; 16:289-303. [PMID: 32144398 DOI: 10.1038/s41581-020-0260-2] [Citation(s) in RCA: 70] [Impact Index Per Article: 17.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/11/2020] [Indexed: 12/17/2022]
Abstract
The kidney is permeated by a highly complex vascular system with glomerular and peritubular capillary networks that are essential for maintaining the normal functions of glomerular and tubular epithelial cells. The integrity of the renal vascular network depends on a balance of proangiogenic and antiangiogenic factors, and disruption of this balance has been identified in various kidney diseases. Decreased levels of the predominant proangiogenic factor, vascular endothelial growth factor A (VEGFA), can result in glomerular microangiopathy and contribute to the onset of preeclampsia, whereas upregulation of VEGFA has roles in diabetic kidney disease (DKD) and polycystic kidney disease (PKD). Other factors that regulate angiogenesis, such as angiopoietin 1 and vasohibin 1, have been shown to be protective in animal models of DKD and renal fibrosis. The renal lymphatic system is important for fluid homeostasis in the kidney, as well as the transport of immune cells and antigens. Experimental studies suggest that the lymphangiogenic factor VEGFC might have protective effects in PKD, DKD and renal fibrosis. Understanding the physiological and pathological roles of factors that regulate angiogenesis and lymphangiogenesis in the kidney has led to the development of novel therapeutic strategies for kidney diseases.
Collapse
|
17
|
Li Y, Li J, Hou Y, Huang L, Bian Y, Song G, Qiao C. Circadian clock gene Clock is involved in the pathogenesis of preeclampsia through hypoxia. Life Sci 2020; 247:117441. [PMID: 32074481 DOI: 10.1016/j.lfs.2020.117441] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2019] [Revised: 02/13/2020] [Accepted: 02/14/2020] [Indexed: 01/15/2023]
Abstract
OBJECTIVE To study the effect of the circadian clock gene Clock on the biological behavior of trophoblasts and its role in the pathogenesis of preeclampsia. METHODS Quantitative real-time polymerase chain reaction (RT-qPCR) was used to detect the expression of Clock mRNA. Western blot and immunohistochemistry were used to detect the expression and localization of Clock protein. CoCl2 was used to induce the hypoxic trophoblast cells. Cell invasion assay, wound healing assay and MTT assays were used to detect the invasion, migration, and proliferation ability. Reduced uterine perfusion pressure (RUPP) rat model was established by surgically clamping the abdominal aorta and uterine arteries. Transfection of si-Clock was used to silencing the expression of Clock. RESULTS Clock mRNA expression was increased in placenta of preeclampsia and CoCl2-induced hypoxic trophoblasts, while protein was decreased. But the trend was opposite in RUPP rat models. Hypoxia can also change the expression rhythm of Clock. The proliferation, migration and invasion ability of trophoblasts decreased after hypoxia, while these abilities restored to near normal level after silencing Clock. CONCLUSION The expression of Clock gene in human placenta tissue, hypoxia cell model and RUPP rat model suggests that it may regulate the biological behavior of trophoblast cells through hypoxia, and then participate in the pathogenesis of preeclampsia.
Collapse
Affiliation(s)
- Yuanyuan Li
- Department of Obstetrics and Gynecology, Shengjing Hospital, China Medical University, Shenyang, Liaoning Province, China; Key Laboratory of Maternal-Fetal Medicine, China Medical University, Shenyang, Liaoning Province, China; Key Laboratory of Obstetrics and Gynecology of Higher Education, China Medical University, Shenyang, Liaoning Province, China
| | - Jiapo Li
- Department of Obstetrics and Gynecology, Shengjing Hospital, China Medical University, Shenyang, Liaoning Province, China; Key Laboratory of Maternal-Fetal Medicine, China Medical University, Shenyang, Liaoning Province, China; Key Laboratory of Obstetrics and Gynecology of Higher Education, China Medical University, Shenyang, Liaoning Province, China
| | - Yue Hou
- Department of Obstetrics and Gynecology, Shengjing Hospital, China Medical University, Shenyang, Liaoning Province, China; Key Laboratory of Maternal-Fetal Medicine, China Medical University, Shenyang, Liaoning Province, China; Key Laboratory of Obstetrics and Gynecology of Higher Education, China Medical University, Shenyang, Liaoning Province, China
| | - Ling Huang
- Department of Obstetrics and Gynecology, Shengjing Hospital, China Medical University, Shenyang, Liaoning Province, China; Key Laboratory of Maternal-Fetal Medicine, China Medical University, Shenyang, Liaoning Province, China; Key Laboratory of Obstetrics and Gynecology of Higher Education, China Medical University, Shenyang, Liaoning Province, China
| | - Yue Bian
- Department of Obstetrics and Gynecology, Shengjing Hospital, China Medical University, Shenyang, Liaoning Province, China; Key Laboratory of Maternal-Fetal Medicine, China Medical University, Shenyang, Liaoning Province, China; Key Laboratory of Obstetrics and Gynecology of Higher Education, China Medical University, Shenyang, Liaoning Province, China
| | - Guiyu Song
- Department of Obstetrics and Gynecology, Shengjing Hospital, China Medical University, Shenyang, Liaoning Province, China
| | - Chong Qiao
- Department of Obstetrics and Gynecology, Shengjing Hospital, China Medical University, Shenyang, Liaoning Province, China; Key Laboratory of Maternal-Fetal Medicine, China Medical University, Shenyang, Liaoning Province, China; Key Laboratory of Obstetrics and Gynecology of Higher Education, China Medical University, Shenyang, Liaoning Province, China.
| |
Collapse
|
18
|
Upregulation of VEGF and PEDF in Placentas of Women with Lower Extremity Venous Insufficiency during Pregnancy and Its Implication in Villous Calcification. BIOMED RESEARCH INTERNATIONAL 2019; 2019:5320902. [PMID: 31886225 PMCID: PMC6925773 DOI: 10.1155/2019/5320902] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/01/2019] [Accepted: 10/17/2019] [Indexed: 12/14/2022]
Abstract
Pregnancy is a period in a woman's life in which changes can occur that affect different physiological processes. Common conditions during this period include vascular changes, such as lower extremity venous insufficiency (VI). This is an observational, analytical, and prospective cohort study in which 114 pregnant women were analyzed, of which 62 were clinically diagnosed with VI. In parallel, 52 control patients without VI (HC) were studied. The aim of this study was to observe changes in angiogenesis and inflammation markers as well as the presence of calcium deposits. The expression of vascular endothelial growth factor (VEGF), transforming growth factor-β (TGF-β), and pigment epithelium-derived factor (PEDF) was analyzed by immunohistochemistry and RT-qPCR. The presence of calcium deposits was revealed using the von Kossa method. In the placentas of mothers with VI, gene expression of VEGF (34.575 [32.380–36.720] VI vs 32.965 [30.580–36.320] HC) and PEDF (25.417 [24.459–27.675] VI vs 24.400 [23.102–30.223] HC) significantly increased, as was protein expression in the placental villi. An increase in calcium deposits was observed in the placentas of women with VI (72.58% VI/53.84% HC). This study revealed the existence of cellular damage in the placental villi of mothers with VI with tissue implications such as increased calcification.
Collapse
|
19
|
Chen X, Xi X, Cui F, Wen M, Hong A, Hu Z, Ni J. Abnormal expression and clinical significance of 25-hydroxyvitamin D and sFlt-1 in patients with preeclampsia. J Int Med Res 2019; 47:4673-4682. [PMID: 31510832 PMCID: PMC6833401 DOI: 10.1177/0300060519860979] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Objective To determine the association between levels of serum 25-hydroxyvitamin D (25[OH]D) and soluble fms-like tyrosine kinase 1 (sFlt-1) in patients with preeclampsia. Methods Clinical and demographic data were collected from patients with preeclampsia and healthy pregnant controls. Serum 25(OH)D and sFlt-1 levels were evaluated by enzyme-linked immunosorbent assay and their correlations were determined using Spearman’s rank correlation coefficient. Associations between serum 25(OH)D and sFlt-1 levels and disease severity and clinical parameters were evaluated. Results Significantly lower serum 25(OH)D and higher sFlt-1 levels were observed in patients with preeclampsia (n = 100) versus controls (n = 100), and 25(OH)D was inversely correlated with sFlt-1 in patients with preeclampsia. Serum 25(OH)D levels were reduced, while sFlt-1 concentration was increased in patients with severe versus mild preeclampsia. Serum 25(OH)D levels were reduced in late-onset versus early-onset severe preeclampsia. Patients with preeclampsia who had lower serum 25(OH)D or elevated sFlt-1 levels showed significantly higher blood pressure indexes versus those with higher 25(OH)D or lower sFlt-1. Conclusions Low serum 25(OH)D and high sFlt-1 may be candidate biomarkers for preeclampsia diagnosis and prognosis.
Collapse
Affiliation(s)
- Xinhua Chen
- Department of Obstetrics, Wuhu First People's Hospital, Wuhu city, Anhui province, China
| | - Xuxia Xi
- Department of Obstetrics, Wuhu First People's Hospital, Wuhu city, Anhui province, China
| | - Fan Cui
- Inspection Division, Wuhu First People's Hospital, Wuhu city, Anhui province, China
| | - Ming Wen
- Department of Obstetrics, Wuhu First People's Hospital, Wuhu city, Anhui province, China
| | - Aijuan Hong
- Department of Obstetrics, Wuhu First People's Hospital, Wuhu city, Anhui province, China
| | - Zemei Hu
- Department of Obstetrics, Wuhu First People's Hospital, Wuhu city, Anhui province, China
| | - Juan Ni
- Department of Obstetrics, Wuhu First People's Hospital, Wuhu city, Anhui province, China
| |
Collapse
|